518344-01-9

Upstream product

• 518343-91-4 2-acetylamino-2-{2-[4-(1-ethoxycarbonyl-1-methyl-ethoxy)phenoxy]-ethyl}-malonic acid diethyl ester 
• 518344-00-8 2-amino-4-[4-(1-ethoxycarbonyl-1-methyl-ethoxy)-phenoxy]-butyric acid ethyl ester 
• 518343-90-3 2-[4-(2-bromoethoxy)-phenoxy]-2-methyl-propionic acid ethyl ester 
• 100-52-7 benzaldehyde 
• 42806-90-6 2-(4-hydroxyphenoxy)-2-methyl propionic acid ethyl ester 
• 14002-51-8 4-biphenyl-carboxylic acid chloride 
• 518343-99-2 2-benzylamino-4-[4-(1-ethoxycarbonyl-1-methyl-ethoxy)-phenoxy]-butyric acid ethyl ester 

Downstream Products

• 328918-72-5 2-{4-[2-(2-biphenyl-4-yl-5-trifluoromethyl-oxazol-4-yl)-ethoxy]-phenoxy}-2-methyl-propionic acid 
• 328920-00-9 2-{4-[2-(2-biphenyl-4-yl-5-trifluoromethyl-oxazol-4-yl)-ethoxy]-phenoxy}-2-methyl-propionic acid methyl ester 
• 518344-02-0 2-[benzyl-(biphenyl-4-carbonyl)-amino]-4-[4-(1-carboxy-1-methyl-ethoxy)-phenoxy]-butyric acid 

Relevant academic research and scientific papers

Application of the Dakin-West reaction for the synthesis of oxazole-containing dual PPARα/γ agonists

An improved method for the preparation of a series of oxazole-containing dual PPARα/γ agonists is described. A synthetic sequence utilizing a Dakin-West reaction was devised that allows for the introduction of the oxazole ring either late in the synthetic sequence via aminomalonate-derived chemistry or in pivotal SAR intermediates derived from aspartic acid.

Modulators of peroxisome proliferator activated receptors

The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented b